Monoclonal Genomic Antibody Technology®

For development of monoclonal antibodies with Genomic Antibody Technology®, SDI selects three regions of your protein for in vivo expression. This increases the probability of obtaining useful monoclonal antibodies. Sera and supernatants are tested by SDI using immunogen expressed in the laboratory. We send sera and supernatant as well as the results of our testing for your evaluation. Cryopreserved hybridoma cell lines are the product. These cell lines can be used for monoclonal antibody production.

There are two phases for development of monoclonal antibodies with Genomic Antibody Technology®:

Phase I:  Development of Immune Mice
Timing:  84 days from receipt of protein sequence to selection of mice for cell fusion
Price:  Please call
Phase II:  Development of Monoclonal Antibodies with Genomic Antibody Technology®
Timing:  84 days from start of fusion work to delivery of final report
Price:  Please call

Total project time: 168 days
Total project price: Please call



Important Information

  • For research use only.
  • All work is fee-for-service.


    • Ready to Order?

    You can order Genomic Antibody Technology™ online by submitting your genetic sequence using your STAR Account. You can use a purchase order or your credit card to order online today.

    Sign in to your STAR Account, or register to create one.

    The latest from SDI Antibodies

  • SDI Selected as Key Supplier to SAIC-F and the National Cancer Institute for the Development of a Comprehensive Portfolio of Antibodies for use in Cancer Research. more more

  • SDI to Produce Library of Antibodies for the Study of Usher Syndrome. more more

  • SDI Enters Supply Agreement for Antibody Library for Study of Chromosome Proteins with University of North Carolina Chapel Hill more more

  • SDI Announces Progress in Advancing Clinical Biomarker Discovery, Successful Application of Technology in Cancer Biomarker Identification at M.D. Anderson Cancer Center more more

  • Strategic Diagnostics Inc. Announces Partnership with the University of Delaware and the Helen F. Graham Cancer Center to Develop Cancer Assays more more

  • SDI Announces Success in Demonstrating Utility of its Proprietary Genomic Antibody Technology™ Reagents on Clinical Samples in Cooperation with the Human Protein Atlas more more
    • Attend a Genomic Antibody Technology™ Webinar.
    • More dates coming soon.

    To register, send a message to GATWebinar@sdix.com